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Abstract
Genome‐wide association studies (GWAS) have identified single‐nucleotide poly-
morphisms (SNPs) associated with glioma risk on 20q13.33, but the biological me-
chanisms underlying this association are unknown. We tested the hypothesis that a
functional SNP on 20q13.33 impacted the activity of an enhancer, leading to an
altered expression of nearby genes. To identify candidate functional SNPs, we
identified all SNPs in linkage disequilibrium with the risk‐associated SNP rs2297440
that mapped to putative enhancers. Putative enhancers containing candidate
functional SNPs were tested for allele‐specific effects in luciferase enhancer activity
assays against glioblastoma multiforme (GBM) cell lines. An enhancer containing
SNP rs3761124 exhibited allele‐specific effects on activity. Deletion of this en-
hancer by CRISPR‐Cas9 editing in GBM cell lines correlated with an altered ex-
pression of multiple genes, including STMN3, RTEL1, RTEL1‐TNFRSF6B, GMEB2, and
SRMS. Expression quantitative trait loci (eQTL) analyses using nondiseased brain
samples, isocitrate dehydrogenase 1 (IDH1) wild‐type glioma, and neurodevelop-
mental tissues showed STMN3 to be a consistent significant eQTL with rs3761124.
RTEL1 and GMEB2 were also significant eQTLs in the context of early CNS devel-
opment and/or in IDH1 wild‐type glioma. We provide evidence that rs3761124 is a
functional variant on 20q13.33 related to glioma/GBM risk that modulates the
expression of STMN3 and potentially other genes across diverse cellular contexts.
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1 | INTRODUCTION
Gliomas are the most common form of brain cancer, accounting for
around 13,000 deaths in the USA each year (Bondy et al., 2008;
Ostrom et al., 2015). Gliomas are a heterogeneous group of tumors,
which are typically associated with a poor prognosis. The most
common type of glioma, glioblastoma multiforme (GBM), has a
median overall survival of only 10–15 months (Bondy et al., 2008).
Genome‐wide association studies (GWAS) of glioma have led to
the discovery of at least 25 inherited risk variants (Kinnersley et al.,
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2018). These 25 loci, in total, are estimated to account for approxi-
mately 30% of heritable risk (Melin et al., 2017). The discovery of the
biological mechanism underlying these risk variants has the potential
to reveal novel insights into glioma development. However, char-
acterization of the biological basis of risk has proven to be challen-
ging, because few index GWAS single‐nucleotide polymorphisms
(SNPs) are themselves functional. The emerging picture is that most
functional/causal SNPs associated with risk map to enhancers or
promoters and lead to an altered gene expression (Biancolella et al.,
2014; Fortiniini et al., 2014).
Several GWAS and GWAS meta‐analyses have identified
20q13.33 as a risk locus, especially its association with isocitrate
dehydrogenase 1 (IDH1) wild‐type or TERT (telomerase reverse
transcriptase)‐only gliomas. (Eckel‐Passow et al., 2015; Enciso‐Mora
et al., 2013; Kinnersley et al., 2015; Labreche et al., 2018; Rajaraman
et al., 2012; Sanson et al., 2011; Shete et al., 2009; Walsh et al., 2014;
Wrensch et al., 2009; Wu et al., 2019). In the first two GWAS con-
ducted on glioma, several risk variants were identified that reached
genome‐wide significance in 20q13.33, with rs6010620
(NC_000020.10:g.62309839A>G) being the common risk SNP be-
tween the two studies (Shete et al., 2009; Wrensch et al., 2009).
Subsequent GWAS further confirmed 20q13.33 as a risk locus
(Kinnersley et al., 2015; Rajaraman et al., 2012), with the most recent
and largest Glioma International Case‐Control (GICC) GWAS meta‐
analysis (cases: 12,496, controls: 18,190) again confirming the as-
sociation between a polymorphism in 20q13.33 and glioma, and the
top GWAS SNP as rs2297440 (GICC GWAS meta‐analysis p = 1.16E
−38; NC_000020.10:g.62312299T>C; Melin et al., 2017), where the
association was strongest with GBM. These studies reveal that
20q13.33 is among the most consistently validated GWAS locus for
glioma/GBM. However, functional variants within the region have
yet to be identified.
The top GWAS SNP at 20q13.33, rs2297440, maps to Intron 14
of the regulator of telomere elongation helicase 1 (RTEL1). It is un-
likely that this SNP is functional/causal, as it does do not map to any
functional elements, including enhancers, in astrocytes or cortical
tissues (data not shown). We, therefore, tested the hypothesis that
the functional/causal SNP(s) in this region were in linkage dis-
equilibrium (LD) with this top GWAS SNP. To identify candidate
functional variants within the 20q13.33 GWAS locus, we systemi-
cally screened SNPs in LD with rs2297440 that intersected with
regulatory elements/enhancers as cataloged in publicly available
annotations. Each candidate enhancer/SNP region identified was
tested in luciferase reporter assays for SNP‐dependent allele‐specific
effects on enhancer activity. Using this approach, we identified a
functional SNP rs3761124 that mapped to an enhancer region on
20q13.33. This SNP had allele‐specific effects on enhancer activity in
cell‐based luciferase reporter assays. Several candidate target genes
of this enhancer were identified after CRISPR‐Cas9 deletion in-
cluding stathmin 3 (STMN3). We further demonstrated that this
variant correlated with the expression of several cis genes using
eQTL analysis, including STMN3 as the most consistent target gene
across different cellular contexts.
2 | MATERIALS AND METHODS
2.1 | Region analysis
Several GWAS have shown an association between SNPs mapping to
chromosome 20q13.33 and glioma risk (Kinnersley et al., 2015; Melin
et al., 2017; Rajaraman et al., 2012; Shete et al., 2009). We identified an
LD block of approximately 116kb on chromosome 20q13.33, which
included 120 SNPs (Figure 1) in LD with the lead SNP in the most
recent GWAS meta‐analysis (rs2297440; Melin et al., 2017). LD was
determined by r2 > = .6 in the CEU population. To identify candidate
functional SNPs, we used University of California Santa Cruz Genome
Browser (http://genome.ucsc.edu/; Kent et al., 2002) to overlay the
SNPs in LD with rs2297440 with physiologically relevant histone ChIP‐
Seq peaks for H3K4me1 (from Encyclopedia of DNA Elements [EN-
CODE] normal human astrocyte cell line GSM733710) and H3K27ac
(from ENCODE normal human astrocyte cell line GSM733763 and
ENCODE GBM cell line GSM1121878; Figure 1). All cloned candidate
enhancer regions contained at least one SNP in LD (r2 > = .6) with the
lead SNP (rs2297440) and coincided with peaks of chromatin marks of
enhancers in at least two relevant ChIP‐seq datasets. Additional histone
ChIP‐Seq peaks for enhancer elements derived from normal human
astrocytes, human glioblastoma cancer stem cells, and human glio-
blastoma cell lines were also used in these analyses (GSM1121881,
GSM894065, GSM1515744, GSM2500170, GSM1121859, and
GSM1121869; data are not shown). This analysis resulted in the iden-
tification of four candidate enhancer elements that each contained at
least one SNP in LD with rs2297440 (Figure 1).
2.2 | Cell culture
LN‐229 and U‐87 MG GBM cell lines were obtained from Amer-
ican Type Culture Collection. LN‐229 cells were grown in Dul-
becco's modified Eagle's medium (DMEM; Thermo Fisher
Scientific) supplemented with 5% fetal bovine serum (FBS; Thermo
Fisher Scientific) and 1% penicillin/streptomycin, and incubated at
37°C and 5% CO2. U‐87 MG cells were grown in DMEM (Thermo
Fisher Scientific) supplemented with 10% FBS (Thermo Fisher
Scientific) and 1% penicillin/streptomycin, and incubated at 37°C
and 5% CO2.
2.3 | Plasmids and luciferase assays
DNA fragments containing alternate alleles of each of the four
candidate SNPs/haplotypes were polymerase chain reaction (PCR)‐
amplified from normal human genomic DNA and subcloned into Sac I
and Xho I restriction enzyme sites (in both orientations) upstream of
a thymidine kinase (TK) minimal promoter‐driven firefly luciferase
vector (courtesy of Dr. G. A. Coetzee, Van Andel Research Institute)
using CloneAmp HiFi PCR Premix and the In‐Fusion HD cloning kit
(Takara). Plasmid clones were sequenced by Sanger sequencing
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(Genewiz) to confirm the presence of the candidate variants and the
absence of any PCR amplification‐induced mutations.
A region of 1p31.3, previously shown to have no activity in any
of the cell lines, served as the negative control, and a region of
11q23.3, previously shown to have enhancer activity in all of the cell
lines, served as the positive control. For enhancer assays, LN‐229
(25 × 103 cells/well) and U‐87 MG cells (7 × 104 cells/well) were
seeded into 96‐well plates. Cells were cotransfected with reporter
plasmids and constitutively active pNL1.1.TK [Nluc/TK] Vector
(Promega) using Lipofectamine 2000 Reagent (Thermo Fisher Sci-
entific) according to the manufacturer's instructions. After 48 h, cells
were assayed for luciferase activity using the Dual‐Luciferase Re-
porter Assay System (Promega), according to the manufacturer's
instructions, and measured using a Synergy H1 Microplate Reader
(BioTek). To quantify enhancer activity in cells transfected with
candidate enhancer elements, luminescence resulting from the
transcription and translation of firefly luciferase in the presence of
luciferin was measured, and background luminescence in the absence
of reagents was subtracted. To control for cell concentration, nor-
malization with luminescence from constitutively active NanoLuc
luciferase was performed (i.e., candidate enhancer/constitutive con-
trol). To control for assay artifact, normalization with luminescence
from cells transfected with clones empirically found to have no en-
hancer activity was performed (i.e., candidate enhancer/negative
control). Measurements for each enhancer were obtained in three
wells (i.e., technical replicates) for four clones (i.e., biological re-
plicates) for each of the two alleles observed in human populations
(i.e., experimental conditions) on three separate days (i.e., experi-
mental validations) and in two independent cell lines (i.e., experi-
mental validations). For statistical testing, measurements from the
two cell lines were considered separately, and regression analysis
was performed with generalized estimating equations to account for
repeated measurements of clones (Goldhoff et al., 2008; Zeger &
Liang, 1986).
2.4 | CRISPR‐Cas9 genome editing
Upstream and downstream CRISPR gRNAs (guide RNAs) were de-
signed flanking the candidate enhancer regions, using https://www.
crisprscan.org/ (Moreno‐Mateos et al., 2015; guide sequences;
gRNA1: 5' GCCATGTACGACCTGGGAAC, gRNA2: 5' GCTGCGTG
ACCGCGCACGGC), and cloned into modified transient expression
plasmid from Addgene (42230). Briefly, the plasmid was digested
with PstI and self‐ligated to obtain only gRNA expressing plasmid.
CACC and AAAC overhangs were added on the 5’ of the oligos (In-
tegrated DNA Technologies) and then self‐annealed to produce in-
serts. Later, modified plasmid was digested with BbsI to produce a
vector that is ligated with annealed oligos in the presence of DNA
Ligase IV (New England Biolabs) to produce gRNA expressing plas-
mids (gRNA1 Forward: 5′CACCGCCATGTACGACCTGGGAAC,
gRNA1 Reverse: 5′AAACGTTCCCAGGTCGTACATGGC; gRNA2
Forward: 5′CACCGCTGCGTGACCGCGCACGGC, gRNA2 Reverse:
5′AAACGCCGTGCGCGGTCACGCAGC). The Cas9‐expressing plas-
mid was purchased from Addgene (41815). LN‐229 and U‐87 MG
cells were transfected by gRNA‐ and Cas9‐expressing plasmids (1:3
ratio) using Lipofectamine 2000 (Thermo Fisher). Transfected cells
were selected by at least 5‐day treatment with geneticin (1 mg/ml for
LN‐229 cells and 0.5mg/ml for U‐87 MG cells) before DNA and RNA
harvesting. Genomic DNA was purified using the QIAamp DNA Mini
F IGURE 1 The region of chromosome 20 associated with glioblastoma risk. A detailed view of the region defined by LD block with lead SNP
rs2297440, r2 > .6 in CEU population, using the UCSC Genome Browser showing putative enhancer elements containing SNPs in LD with
rs2297440. SNPs in LD are observed below genes in the region. Histone ChIP‐Seq tracks for H3K27ac from normal human astrocytes (NHA),
MGG8 glioblastoma stem cells, and H3K4me1 from NHA aligned below SNPs indicate potential enhancer elements. Region 1 denotes a region
with no enhancer activity in luciferase assays. Region 2 denotes the allele‐specific enhancer region, which includes rs3761124 (marked with an
asterisk). Regions 3 and 4 denote regions that exhibited enhancer activity but were unaffected by haplotype. It should be noted that the size of
the regions tested for enhancer activity is not to scale. LD, linkage disequilibrium; SNP, single‐nucleotide polymorphism; UCSC, University of
California Santa Cruz
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Kit (Qiagen) and enhancer deletion was confirmed with PCR ampli-
fications (forward primer: 5′ GCCTGACCAACATGATGAAA, reverse
primer: 5′ TGGCCAGTGAACCTCACTTC).
2.5 | Quantitative Real‐Time PCR
RNA was isolated using Trizol reagent (Thermo Fisher) and cDNA was
synthesized from 2 μg of total RNA using the High‐Capacity Reverse
Transcriptase cDNA Kit (Thermo Fisher Scientific). The quantitative
real‐time polymerase chain reaction (RT‐PCR) was performed using
Superscript III Kit for RT‐PCR (Thermo Fisher Scientific) and amplified
with TaqMan assays for genes mapping within 250‐kb upstream and
downstream of SNP rs3761124: RTEL1 (assay ID: Hs01566915_m1),
RTEL1‐TNFRSF6B (Hs01548060_m1), Src‐related kinase lacking C‐
terminal regulatory tyrosine and N‐terminal myristylation site (SRMS;
Hs00998384_m1), glucocorticoid modulatory element binding protein 2
(GMEB2; Hs00202606_m1), STMN3 (Hs00274822_m1), ADP ribosyla-
tion factor‐related protein 1 (ARFRP1; Hs00182389_m1), protein tyr-
osine kinase 6 (PTK6; Hs00966641_m1), SLC2A4 regulator (SLC2A4RG;
Hs00219920_m1), eukaryotic translation elongation factor 1 alpha 2
(EEF1A2; Hs00951278_m1), pancreatic progenitor cell differentiation
and proliferation factor (PPDPF; Hs01100976_g1), helicase with zinc
finger 2 (HELZ2; Hs00375688_m1), fibronectin type III domain‐
containing 11 (FNDC11; Hs01868475_s1), zinc finger CCCH‐type and
G‐patch domain containing (ZGPAT; Hs00738790_m1), Lck‐interacting
transmembrane adapter 1 (LIME1; Hs00942226_g1), zinc finger and
BTB domain‐containing 46 (ZBTB46; Hs01008166_m1), abhydrolase
domain‐containing 16B (ABHD16B; Hs00607796_s1), DnaJ heat shock
protein family (Hsp40) member C5 (DNAJC5; Hs01122831_m1), tumor
protein D52 like 2 (TPD52L2; Hs00900580_g1), and TBP (internal
control; Hs00427620_m1) in three independent experiments and in
triplicate for each RNA preparation on QuantStudio 5 (Thermo Fisher
Scientific), and analyzed using GraphPad Prism (version 8.3.0, GraphPad
Software; www.graphpad.com). Reactions were normalized using the
control gene TBP, and calculations were performed according to the
‐2 CΔΔ t method. Fold change in the expression was determined from
three independent experimental repeats, each performed in duplicate,
unless otherwise noted. Data were analyzed for statistical differences
using an analysis of variance, with Bonferroni correction for multiple
hypothesis testing. *p < .05; **p < .01; and ***p < .001 indicate the levels
of significance.
2.6 | eQTL mapping
The association between rs3761124 and expression of cis genes
was evaluated in adult brains without neurological diseases,
during early neurological development, and in IDH1 wild‐type
adult glioma. To perform eQTL analyses across these different
biological contexts, data sets generated from the CommonMind
Consortium (CMC), the University of California, Los Angeles
(UCLA) postconception fetal tissues collection, and The Cancer
Genome Atlas (TCGA) GBM and lower grade glioma (LGG) co-
horts were used.
Approval was obtained from the National Institute of Mental
Health to use the control brain dataset of CMC release 1. These data
were generated in postmortem brain tissues, previously verified to
be free of any neurological diseases. The eQTL analysis included the
genotyping and RNA‐seq data of a total of 216 unique individuals of
European ancestry. RNA‐Seq FASTQ files of CMC were downloaded
from https://www.synapse.org/ (syn2759792) and mapped to hg19
using STAR (Dobin et al., 2013), with Gencode v19 as the reference
annotation. FeatureCounts from the Subread package (http://
subread.sourceforge.net/) was used to generate gene‐level counts
from the aligned reads. All genes included in the analysis had more
than five reads across all samples, and less than 10 samples per gene
had zero reads. The filtered counts of the target genes were nor-
malized using the variance‐stabilizing transformation in DESeq2
(Love et al., 2014). Genotyping data of rs3761124 were extracted
from Illumina Infinium HumanOmniExpressExome array data (plink
file), and the alleles were matched to the forward strand of GRCh37
reference genome using the Bcftools fixref plugin (http://www.htslib.
org/doc/#publications). Linear regression was used to evaluate the
association between rs3761124 and specific target genes discovered
by quantitative RT‐PCR, with age, gender, RIN scores, the first three
principal components of genotype, and RNA‐seq expression residuals
as covariates.
To evaluate the effect of rs3761124 on gene expression during
early neurological development, a dataset generated from resources
of the UCLA Gene and Cell Therapy core (Walker et al., 2019) was
obtained from dbGAP, which approved the use of genotyping and
RNA‐seq data of 219 donors of European ancestry (postconception
weeks 14−21). RNA‐seq SRA files were converted to FASTQ format
using the fastq‐dump utility of the SRAtoolkit v2.10.5 (http://ncbi.
github.io/sra-tools/), followed by processing of FASTQ files using the
same pipeline (as CMC dataset) to obtain, filter, and normalize gene
counts. Data for the functional SNP rs3761124 were extracted from
the processed genotype data in PLINK format (Purcell et al., 2007),
and the alleles were matched with the forward strand of GRCh37
reference genome using the Bcftools fixref plugin. eQTL mapping
was performed in the same way as normal brain tissues using linear
regression, except the covariate age that was substituted as gesta-
tional age.
To evaluate eQTL after glioma is established, the combined
cohort of GBM and LGG from TCGA was used (Ceccarelli et al.,
2016). As the 20q13.33 locus is most relevant to the subset of
IDH1 wild‐type glioma, IDH1 wild‐type subjects were identified in
the cBioPortal and corresponding clinical, RNA‐seq BAM files,
and preprocessed copy number alteration data were downloaded
through the CDG portal. Germline genotype files (Affymetrix
SNP 6.0 level 2 data) were downloaded from the GDC Legacy
Archive and included a total of 211 IDH1 wild‐type subjects of
European ancestry. Access to controlled TCGA data was ap-
proved by dbGAP. Genotyping data were first converted to calls
with confidence scores of more than 0.9. Afterward, SNPs were
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checked for concordance with 1000 Genomes, flipped to the
positive strand accordingly, and then SHAPE‐IT and IMPUTE2
were used to phase and impute SNPs on 20q13.33, including
rs3761124 (IMPUTE2 info score 0.9; Delaneau et al., 2008;
Howie et al., 2009). RNA‐seq BAM files were converted to
FASTQ format using SAMtools and BEDtools (Li et al., 2009;
Quinlan & Hall, 2010). Downstream processing of FASTQ files
was performed as previously mentioned. As the effect of the
functional SNP on gene expression can be confounded by seg-
mental and focal copy number variations (CNVs) in tumors,
segmental CNV data (Level 3) were also collected from TCGA.
Segment means were generated by reverse log2 transformation
of the segmented copy number values. Focal‐level CNV values of
candidate target genes STMN3, SRMS, RTEL1, RTEL‐TNFRSF6B,
and GMEB2 were retrieved from the masked copy number seg-
ment files, which were generated using GISTIC2 (Beroukhim
et al., 2010). eQTL mapping was performed similar to the CMC
and UCLA datasets, with the addition of focal and segmental CNV
values as covariates in linear regression analyses.
As all eQTL analyses were hypothesis‐driven and were guided by
significant results of quantitative RT‐PCR of cis genes following
CRISPR‐Cas9 experiments, there was no type‐1 error adjustment of
the results.
2.7 | Colocalization of eQTL and GWAS signals
To provide additional supporting data that the functional SNP
rs3761124 is likely responsible for the signals in both GWAS and
eQTL analyses, the most concordant eQTL result was colocalized
with the GICC GWAS meta‐analysis summary result (case:
12,496, control: 18,190; Melin et al., 2017). The GICC GWAS
meta‐analysis result for rs3761124 was highly significant (β = .29
(.02), p = 1.3E‐37). We used the COLOC software to evaluate the
posterior probability that the genetic association with gene ex-
pression is driven by the same variant driving the GWAS risk
association (termed PP4; Giambartolomei et al., 2014). The
method also evaluates if the expression association and disease
association are driven by two distinct causal variants (PP3). A
high PP4 (>0.8) and low PP3 (<0.2) indicate that a single
variant (rs3761124) is responsible for both the GWAS and eQTL
signals.
2.8 | Visualization of Hi‐C chromosome
conformation interactions
The 3D Genome Browser (http://3dgenome.org) was used to vi-
sualize Hi‐C data in 20q13.33 in GBM cell line G583 (Johnston
et al., 2019; Wang et al., 2018). The bait region contained
rs3761124, and the browser extracted Hi‐C data centered on the
bait region and presented interaction events as peak signals in
nearby or distal genomic regions; hence, virtual 4C data were
constructed from Hi‐C data, with resolution (bin size) at
5,000 bp.
3 | RESULTS
3.1 | Candidate enhancer region characterization
All four putative enhancers shown in Figure 1 were cloned sepa-
rately into luciferase enhancer activity vectors (Biancolella et al.,
2014; Fortiniini et al., 2014), and enhancer activities of different
alleles were independently tested with measurements of lumines-
cence after transfection of constructs into two GBM cell lines, LN‐
229 and U‐87 MG. Three of the four regions (Regions 2, 3, and 4 in
Figure 1) demonstrated enhancer activity in cell lines in at least one
orientation (data are not shown). There were a total of six SNPs (r2
of ≥ .6 with rs2297440) within these three enhancer regions
(rs3761124 [NC_000020.10:g.62288752T>C] in Region 2,
rs1291209 [NC_000020.10:g.62330439T>C] and rs1295810
[NC_000020.10:g.62330484G>A] in Region 3, and rs1741708
[NC_000020.10:g.62372041G>T], rs2253823 [NC_000020.10:
g.62372956C>T], and rs2253829 [NC_000020.10:g.62373079G>
C] in Region 4), but only one, rs3761124, in the enhancer Region 2
(Figure 1) demonstrated allele‐specific effects. rs3761124 is
23.7 kb away from the top GWAS SNP, rs2297440, and is in high LD
with it (r2 of .92 in the European population). Whereas the candi-
date enhancer in Region 2 demonstrated activity in luciferase as-
says in both directions, rs3761124 showed allele‐specific effects on
enhancer activity in the forward orientation only (Figure 2), and not
the reverse orientation in either cell line (data not shown). The
fragment containing the T allele (the reference allele) correlated
with higher activity than the fragment containing the C allele (the
minor allele) in both of the cell lines and all of the replicates tested.
Region 1 did not show enhancer activity in either of the
two cell lines tested (Figure 1). rs201497780 (NC_000020.10:
g.62284926_62284927delGA) within Region 1 did not demonstrate
enhancer activity in cell lines (Figure 1).
3.2 | CRISPR−Cas9 enhancer disruption
To provide evidence that the candidate functional SNP rs3761124
identified in our cell‐based luciferase assays correlated with the altered
expression of genes mapping in cis, we used CRISPR−Cas9 genome
editing to delete the region containing SNP rs3761124. The GBM cell
lines LN‐229 and U‐87 MG were chosen for these experiments because
they both expressed detectable levels of many of the potential target
genes in the region and due to the demonstrated enhancer activity of
the fragment containing rs3761124 in these cell lines. We designed
guide RNAs (gRNA1 and gRNA2) to delete an approximately 500‐bp
fragment containing the enhancer and SNP rs3761124 (Figure 3a).
Each target sequence was cloned into a gRNA expression plasmid and
used together with Cas9 expression plasmids to induce targeted
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deletion. LN‐229 and U‐87 MG cells were transfected with either Cas9‐
only expressing vector, Cas9 vector and gRNA empty vector, or Cas9
vector and guide RNA target vectors. Transfected cells were placed
under geneticin selection for at least 5 days, after which DNA was
harvested and used to assess the deletion efficiency. Deletion efficiency
was measured by PCR using primers designed to amplify an approxi-
mately 2‐kb region across the putative enhancer containing the candi-
date functional SNP rs3761124 (PCR Forward and PCR Reverse in
Figure 3a). The cell population with the unedited genome revealed a
2‐kb band, whereas the population with the edited cells revealed two
bands: the unedited 2‐kb fragment and the edited 1.5‐kb fragment. Our
results show that a large proportion of cells (though not all) in both cell
lines were successfully edited (Figure 3b,c). RNA was isolated from the
same cellular pools, and the expression of genes within 250 kb in each
direction for which a TaqMan assay was available was tested by qPCR.
3.3 | Gene expression analysis
A number of genes mapping to chromosome 20q13.33 have been im-
plicated in glioma risk (Atkins et al., 2019). We hypothesized that
CRISPR−Cas9 mediated disruption of the region containing the candi-
date functional SNP rs3761124 may affect the expression of multiple
genes. To test this hypothesis, we quantified gene expression within
250 kb on either side of the rs3761124 using Taqman qPCR expression
assays in CRISPR genome‐edited GBM cell lines and compared ex-
pression to mock CRISPR‐edited cells. We observed a statistically sig-
nificant reduction in the expression of several genes, including RTEL1,
RTEL1‐TNFRSF6B (RTEL1‐TNFRSF6B readthrough [nonsense‐mediated
mRNA decay [NMD] candidate]), SRMS, and GMEB2 (Figure 4). We also
observed a statistically significant increase in STMN3 expression. We
did not observe statistically significant changes of expression in any of
the following genes: PTK6, ARFRP1, EEF1A2, PPDPF, HELZ2, LIME1,
TPD52L2, ZBTB46, ZGPAT, SLC2A4RG, or DNAJC5 (data are not shown).
No detectable levels of the following genes were observed in the GBM
cell lines used in our study: KCNQ2 (potassium voltage‐gated channel
subfamily Q member 2), FNDC11, or ABHD16B.
3.4 | eQTL analysis
Table 1 summarizes the eQTL analysis results. STMN3 was a sig-
nificant eQTL with the candidate functional SNP rs3761124 in all
three datasets. RTEL1 was significant in both UCLA and TCGA data
sets, but not in the CMC dataset. GMEB2 was significant only in the
UCLA dataset. Therefore, STMN3 is a consistent eQTL for rs3761124
in early neurological development, in the normal adult brain and in
glioma or during gliomagenesis, whereas the RTEL1 expression cor-
related with rs3761124 only during early neurological development
and in IDH1 wild‐type glioma. Furthermore, GMEB2 is essential
during early neurological development.
3.5 | Colocalization of eQTL and GICC GWAS
meta‐analysis summary statistics
Using the 1000 Genome European population as a reference panel,
COLOC results showed that the PP3 is 0 and PP4 is 0.82 for
F IGURE 2 Allele‐specific enhancer activity of enhancer region 2. All enhancer regions seen in Figure 1 were cloned into a luciferase
enhancer assay construct and tested for enhancer activity. Here, we show data for enhancer region 2 that includes SNP rs13761124 alleles T
and C (four clones for each allele, three independent experiments for each cell line: (+) represents Experiment 1, (×) represents Experiment 2,
and (*) represents Experiment 3. The construct with the T allele demonstrated statistically significantly higher activity than the C allele, as
shown in box plots from LN‐229 (a) and U‐87 MG cells (b).p values represent the probability that the coefficient estimated for allele in the
generalized estimating equation model used to test the effect of allele and experiment on relative luminescence would be observed if the true
effect was zero. SNP, single‐nucleotide polymorphism
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F IGURE 3 CRISPR−Cas9 genome editing of enhancer region 2 on 20q13.33. (a) Chromosome view of the section of putative enhancer
region 2 targeted by CRISPR−Cas9 genome editing technique in the UCSC Genome Browser. The total region (∼2 kb) represents a part of
putative enhancer region 2, containing the candidate functional SNP rs3761124, amplified by PCR (using Forward and Reverse primers). The
region highlighted in gray represents region (∼0.5 kb) targeted by CRISPR gRNAs (gRNA1 and gRNA2). The 1.5‐kb band in DNA gel
electrophoresis demonstrates the targeted deletion of putative enhancer region 2, containing SNP rs3761124, in LN‐229 (b) and U‐87 MG cells
(c). Cas9, cells transfected with Cas9 only (no guide RNAs); Cas9+ control, cells transfected with Cas9 vector and gRNA empty vector; Cas9+
target, cells transfected with Cas9 vector and guide RNA target vectors; NC, mock‐transfected parental cells; PCR, polymerase chain reaction;
SNP, single‐nucleotide polymorphism; UCSC, University of California Santa Cruz
F IGURE 4 The gene expression changes after CRISPR−Cas9 deletion of Enhancer 2. The genomic region corresponding to enhancer region
2 was targeted for deletion in LN‐229 (a) and U‐87 MG (b) cells using CRISPR−Cas9 technology. Pools of transfected cells were analyzed using
qPCR and Taqman gene expression assays for RTEL1, RTEL1‐TNFRSF6B, SRMS, GMEB2, STMN3, PTK6, and TBP(control) custom assays in
triplicate, in three independent experiments. cas9, cells transfected with Cas9 only (no guide RNAs); Cas9+Control, cells transfected with Cas9
vector and gRNA empty vector; Cas9+Target, cells transfected with Cas9 vector and guide RNA target vectors; NC, mock‐transfected parental
cells. Targeting of the region resulted in a decrease in RTEL1, RTEL1‐TNFRSF6B, SRMS, and GMEB2 expression levels, whereas STMN3 expression
levels increased significantly. PTK6 expression levels did not change significantly. *p < .05; **p < .01; and ***p < .001 indicate the levels of
significance
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colocalization of eQTL (CMC dataset: target gene STMN3) and the
corresponding GICC GWAS meta‐analysis summary statistics. This
suggests that rs3761124 has high probability of being a causal var-
iant for both the eQTL and glioma GWAS signals.
3.6 | Visualization of Hi‐C chromosome
conformation interactions
The virtual 4C constructed from Hi‐C data generated from the GBM
cell line, G583, is illustrated in Figure 5. It shows interactions, de-
monstrated as peaks, between the region containing rs3761124 and
promoters of STMN3 and RTEL1.
4 | DISCUSSION
We provide evidence that rs3761124 is a functional SNP on
20q13.33 mapping to a risk enhancer using cell‐based enhancer ac-
tivity assays. We show that rs3761124 had allele‐specific effects on
enhancer activity in the forward direction only. We previously noted
unidirectional, rather than bidirectional, allele‐specific effects on
enhancer activity in colorectal cancer functional studies (Biancolella
et al., 2014; Fortiniini et al., 2014). We further show that this SNP
affects glioma risk potentially through the altered expression of
STMN3, RTEL1, GMEB2, and several other genes based on CRISPR
deletion of the risk enhancer. The complementary methods of eQTL
mapping and Hi‐C interaction data support STMN3, being the most
consistent target gene across biological models, whereas RTEL1 and
GMEB2 expression correlated with rs3761124 only in glioma and/or
during early neurological development but not in the adult normal
brain.
The identification of multiple target genes suggests that this
putative risk enhancer interacts with multiple promoters, some of
which may also depend on additional molecular stimuli. It is not
unprecedented that there may be multiple gene targets of a risk
enhancer. A previous report identified rs73001406 as a candidate
functional variant for glioma on 11q23.3, with PHLDB1 and DDX6 as
potential target genes (Baskin et al., 2015). We previously described
a risk enhancer for colorectal cancer on 11q23.1 that correlated with
the expression of three target genes (Biancolella et al., 2014). Other
studies reported multiple gene targets of risk enhancers in cancers,
such as prostate cancer (Huang et al., 2014) and breast cancer (Betts
et al., 2017; Dunning et al., 2016; Ghoussaini et al., 2016).
STMN3 (also known as SCLIP or SCG10‐like protein) is one of the
members of the stathmin family of proteins that plays an important
role in the regulation of microtubule stability (Charbaut et al., 2001).
In addition to our own finding, the importance of STMN3 in glioma is
supported by other studies. For example, a recent transcriptome‐
wide association study (TWAS), which used the Genotype‐Tissue
Expression Project (GTEx) data to build a gene expression model,
identified STMN3 as a highly significant gene associated with the risk
of adult glioma (4.54 × 10‐27; Atkins et al., 2019). Among 55 adult
tissues analyzed through GTEx, the STMN3 expression is the highest
in the 13 CNS tissues (GTEX portal access 18 June, 2020); further-
more, messenger RNA (mRNA) and protein of this gene are over-
expressed in human glioma of all grades as compared with normal
brain tissues (Zhang et al., 2015). The overexpression of STMN3 in-
creased growth and mobility of glioblastoma cells, whereas STMN3
knockdown impaired cell growth, proliferation, invasion, and migra-
tion (Zhang et al., 2015). Another study reported that high‐resolution
chromosome conformation capture (Hi‐C) data generated in H1
embryonic stem cell and neuronal progenitor cell lines revealed a
physical interaction between the STMN3 promoter and the top
GWAS SNP rs2297440 (Dixon et al., 2015; Labreche et al., 2018),
which is in high LD (r2 = .92) with the functional SNP rs3761124.
Therefore, among the several target genes identified in this study,
STMN3 appears to be the most robust and consistently validated.
Our data also implicate RTEL1 and GMEB2 in glioma, but their
role may be more context‐specific. CRISPR deletion of the risk en-
hancer containing rs3761124 in the U‐87 MG and LN‐229 GBM cell
lines (which are both IDH1 wild type) correlated with altered
TABLE 1 eQTL results of rs3761124: during early brain development (UCLA), in nondiseased adult brain (CMC), and IDH1 wild‐type
glioma (TCGA)
CMC (N = 216) UCLA (N = 219) TCGA (N = 211)
Gene ID Gene Name β (SE)† p β (SE) p β (SE) p
ENSG00000197457.5 STMN3 −.07 (0.02) 1.85 E−4 −.04 (0.01) 2.38 E−3 −.04 (0.02) 1.5 E−02
ENSG00000125508.3 SRMS .01 (0.05) 8.20 E−1 N/Aa N/Aa .02 (0.05) 7.50 E−1
ENSG00000258366.3 RTEL1 −.01 (0.03) 6.32 E−1 .06 (0.02) 1.56 E−2 .06 (0.03) 3.07 E−2
ENSG00000026036.16 RTEL1‐TNFRSF6B .03 (0.03) 2.70 E−1 −.01 (0.03) 6.89 E−1 −.03 (0.03) 3.20 E−1
ENSG00000101216.6 GMEB2 −.01 (0.02) 3.77 E−1 −.06 (0.01) 8.38 E−7 .02 (0.01) 1.23 E−1
Note: Listed results were of the candidate target genes identified by RT‐PCR assays after CRISPR−cas9 deletion of Enhancer 2. Values in bold represent
genes that showed significant association with the functional SNP rs3761124 in the analyzed datasets.
Abbreviations: CMC, CommonMind Consortium; RT‐PCR, real‐time polymerase chain reaction; TCGA, The Cancer Genome Atlas; UCLA, University of
California, Los Angeles.
aThis gene did not pass RNA‐seq Q/A in the UCLA dataset.
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expression of both genes. Consistent with this, rs3761124 correlated
with altered expression of RTEL1 in IDH1 wild‐type glioma and
during early brain development but not in the CMC brain tissues.
This lack of supportive evidence for this gene in the adult normal
brain is also seen in a recent TWAS study, which showed RTEL1 was
not a significant target gene using the GTEx adult nondisease brain
tissues (Atkins et al., 2019). As RTEL1 is a DNA helicase that main-
tains genomic stability directly by suppressing homologous re-
combination, it may be quiescent during normal adult brain, but
becomes increasingly active during conditions of active cellular
growth, such as gliomagenesis and/or during early neurological de-
velopment. Therefore, our candidate functional variant rs3761124
may impact genomic stability through changes in activity of its risk
enhancer, modulating the expression of RTEL1.
Another target gene found in selective context is GMEB2,
which is a transacting factor that binds to glucocorticoid mod-
ulatory elements (GME) present in the Tyrosine Aminotransferase
promoter, increasing sensitivity to glucocorticoid (Oshima et al.,
1995). GMEB2 has been associated with prostate cancer, but its
role in gliomagenesis is unknown. Nevertheless, dexamethasone,
a common corticosteroid with a high glucocorticoid activity, has
been found to significantly increase invasion, cell proliferation,
and angiogenesis in vitro or in vivo in GBM stem cell lines, in-
cluding GBM stem cells that are IDH1 wild‐type (Luedi et al.,
2018). Therefore, it is possible that GMEB2 may be a target gene
in the brain only during conditions of cellular proliferation, such
as at the time of early neurological development and during
gliomagenesis.
F IGURE 5 Visualization of chromosome interactions with rs3761124 in 20q13.33. Virtual 4C was constructed from Hi‐C data of the GBM
cell line, G583. The anchoring point was the location of rs3761124 and also the bait region. Interactions of the bait with genomic regions were
highlighted as peaks in the virtual 4C presentation. The horizontal bar shows the location of the promoter of STMN3 and corresponds to
its interaction peak (contained within the vertical bar). Another interaction peak is observed near the promoter of RTEL1, which is transcribed
in the opposite direction of STMN3,to the right of the anchoring point. GBM, glioblastoma multiforme
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Two additional genes were identified as potential target genes of
the putative risk enhancer on 20q13.33 after CRISPR−Cas9 deletion
including RTEL1‐TNFRSF6B and SRMS. Neither of these genes was
identified in any of our eQTL analyses. RTEL1‐TNFRSF6B is a noncoding,
readthrough transcript that is subject to NMD (Chang et al., 2007), but
it is currently unclear how a change in mRNA decay will affect glioma
development. SRMS belongs to a family of nonreceptor tyrosine kinases
that have been involved in a number of cancers, including fibrosarcoma
(Lin et al., 2013), eosinophilic variant of chromophobe renal cell carci-
noma (Pagano et al., 2018), and breast cancer (Fan et al., 2015), but its
function in gliomagenesis remains unknown. Additional studies will be
required to determine if these genes are indeed relevant to glioma risk.
There are some limitations to our study. We cannot discount the
possibility that there are additional functional SNPs on 20q13.33.
Although we used all available publicly available datasets to identify
candidate enhancers, these may not have captured all relevant en-
hancers across this region. In addition, we restricted our analysis to
SNPs with an r2 > .6 (in CEU population) to the index SNP, and we
may have missed functional SNP(s) that would be captured at a lower
r2. Our in vitro assessment of enhancer activity was conducted in
only two GBM cell lines and we do not know if the candidate en-
hancers that showed no activity in these cells would have been active
in other cell lines. Similarly, our CRISPR deletion experiments were
conducted in GBM cell lines and additional/different target genes of
this enhancer may be seen in more relevant “normal” cells of the
brain. Finally, our eQTL analyses were restricted to data available,
which may not capture all relevant cellular contexts to capture as-
sociations with the functional SNP. Despite this, we believe we
provide strong supportive evidence for the identification of at least
one functional SNP relevant to gliomagenesis on 20q13.33.
In summary, we report identification and characterization of a
functional SNP, rs3761124, that affects the activity of an enhancer
on 20q13.33 that leads to modulated expression of multiple genes
implicated in glioma risk. Our results are concordant with reports by
others that a multiple‐gene, rather than a single‐gene, association
with GBM is present at 20q13.33 (Atkins et al., 2019). As the effect
of these genes on glioma growth and development has not been
evaluated in depth, further studies to evaluate their molecular me-
chanisms may lead to novel therapeutic strategies in the future.
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